Illumina, Inc. (NASDAQ:ILMN) Stake Raised by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 188.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 13,373 shares of the life sciences company's stock after purchasing an additional 8,739 shares during the period. Tower Research Capital LLC TRC's holdings in Illumina were worth $1,787,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Capital World Investors grew its position in shares of Illumina by 408.6% in the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock worth $2,408,721,000 after buying an additional 14,481,232 shares during the last quarter. WCM Investment Management LLC grew its holdings in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after purchasing an additional 867,673 shares during the last quarter. Bank of New York Mellon Corp increased its position in shares of Illumina by 0.8% during the fourth quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares in the last quarter. Norges Bank purchased a new stake in shares of Illumina during the 4th quarter valued at $228,714,000. Finally, Bessemer Group Inc. boosted its position in shares of Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company's stock worth $180,152,000 after purchasing an additional 1,344,038 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Down 0.9 %

Shares of NASDAQ:ILMN traded down $0.66 during trading on Monday, hitting $76.69. The company's stock had a trading volume of 395,826 shares, compared to its average volume of 2,279,107. The company has a market capitalization of $12.14 billion, a PE ratio of -10.00, a PEG ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock's 50-day moving average price is $82.02 and its two-hundred day moving average price is $117.87.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the stock. Robert W. Baird cut their price objective on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. Stephens reaffirmed an "overweight" rating and issued a $156.00 price target on shares of Illumina in a report on Tuesday, March 11th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. Guggenheim lowered their price target on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Finally, Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.